Targeting Human Cancer Stem Cells with Monoclonal Antibodies
Cord Naujokat1,2*

1Institute of Immunology, University of Heidelberg, Im Neuenheimer Feld 305, 69120 Heidelberg, Germany
2Center and Network for Targeted Oncology, Muehlackerweg 8, 69239 Heidelberg, Germany

Abstract
Cancer stem cells (CSCs) constitute a distinct subpopulation of tumor cells that exhibit self-renewal and tumor initiation capacity and the ability to give rise to the heterogeneous lineages of cancer cells that comprise the tumor. CSCs possess various intrinsic mechanisms of resistance to conventional chemotherapeutics, novel tumor-targeted drugs and radiation therapy, permitting them to survive current cancer therapies and to initiate tumor recurrence and metastasis. Different cell surface and transmembrane proteins expressed by CSCs, including CD44, CD47, EpCAM (CD326), CD123, CD133, GD2, Lgr5, insulin-like growth factor receptor I (IGF-IR), and members of the Notch and Wnt signaling pathways, have been identified and mainly used for the characterization of CSCs in experimental settings. Recently, monoclonal antibodies and antibody constructs such as Triomabs and BiTEs raised against these CSC proteins have shown efficacy against CSCs in human xenograft mice, and some of them have been demonstrated to induce tumor regression in clinical trials.

Since current cancer therapies fail to eliminate CSCs, ultimately leading to cancer recurrence and progression, selective targeting of CSCs with mAbs and antibody constructs reviewed herein may represent a novel and promising therapeutic strategy to eradicate cancer.

Keywords: Cancer stem cells (CSCs); Monoclonal antibody (mAb); Antibody construct; Novel drugs; Targeted therapy; Cancer therapy

Introduction
Tumor cell populations are organized as unidirectional cellular hierarchies in which cancer stem cells (CSCs) constitute subsets of cells, which are distinguished from the bulk of the cells that they produce by their ability to indefinitely perpetuate the growth of a malignant cell population. The experimental demonstration of CSCs in a variety of human malignant tumors has led to the conceptual hypothesis that tumors, like physiologic proliferative tissues, are hierarchically organized and propagated by limited numbers of CSCs [1-10]. According to a consensus definition, these CSCs are cells within a tumor that possess the capacity to self-renew and to give rise to the heterogeneous lineages of cancer cells that comprise the tumor [11]. CSCs can be defined experimentally by their ability to recapitulate the generation of a continuously growing tumor in serial xenotransplantation settings [11]. Moreover, recent studies provide evidence for the existence and clinical relevance of CSCs in human cancer [12-14].

CSCs harbor numerous intrinsic mechanisms of resistance to conventional chemotherapeutic drugs, radiation therapy, and novel tumor-targeting drugs that permit CSC survival of current cancer therapies and CSC-mediated initiation of tumor recurrence and metastasis [5,15,16]. Seminal studies indicate that CSCs can even be enriched by conventional chemotherapeutic drug, as demonstrated in breast cancer patients receiving systemic chemotherapy comprising conventional cytotoxic drugs [12,17-19]. Moreover, many novel tumor-targeted drugs, including tyrosine kinase inhibitors and some established monoclonal antibodies (mAbs) fail to eliminate CSCs [20-24], so that there is an urgent need for novel agents and strategies that effectively target CSCs for the use in elaborated clinical settings, preferably in combination with conventional cytostatic drugs, novel tumor-targeted agents, and radiation therapy.

During the past two decades, several mAbs have emerged as effective targeted therapies for the treatment of human malignancies, and various mAbs have been approved and established for the immunotherapy of cancer, most notably the classical mAbs rituximab (anti-CD20) and trastuzumab (anti-HER2) for the treatment of lymphoma and HER2-positive breast cancer, respectively [25,26]. Given their high target antigen specificity and generally minimal toxicity, mAbs and novel antibody constructs are well positioned as potent and specific agents for the elimination of CSCs [27]. In contrast to conventional cytostatic drugs, radiotherapy and novel tumor-targeted drugs, mAbs raised against cancer cell-specific or CSCs-specific cell surface proteins exploit the host’s immune system to eradicate the cells targeted by the mAb by using classical humoral and cellular immune mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), inhibition of receptor-mediated signal transduction, induction of apoptosis, and priming of antigen-presenting cells and effector and memory T cells against targeted tumor antigens [28]. Therefore, targeting of cancer cells and CSCs with specific mAbs and antibody constructs appears not as a single job seen with conventional cytostatic and radiation therapy, but is substantially supported by the host’s immune system.

In the last few years, several mAbs and antibody constructs that selectively target CSCs have been developed and validated. Interestingly, some of these novel agents exhibit not only activity against CSCs, but also against regular tumor cells, as demonstrated by induction of tumor regression in xenograft mouse models and in clinical phase I-III studies (Table 1).

*Corresponding author: Cord Naujokat, Institute of Immunology, University of Heidelberg, Im Neuenheimer Feld 305, 69120 Heidelberg, Germany, Tel: +49 6229 933977; Fax: +49 6229 933978; E-mail: prof.naujokat@gmx.de

Received November 29, 2012; Accepted December 26, 2012; Published December 31, 2012

Citation: Naujokat C (2012) Targeting Human Cancer Stem Cells with Monoclonal Antibodies. J Clin Cell Immunol 55:007. doi:10.4172/2155-9899.55-007

Copyright: © 2012 Naujokat C. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
| Compound | Class | Targets | Clinical Status | References |
|----------|-------|---------|----------------|------------|
| H90 (anti-CD44) | Mouse IgG1 mAb | Acute myeloid leukemia (AML) SCs | Preclinical, xenograft mice | [70] |
| P245 (anti-CD44) | Mouse IgG1 mAb | Breast CSCs | Preclinical, xenograft mice | [77] |
| H4C4 (anti-CD44) | Mouse IgG1 mAb | Pancreatic CSCs | Preclinical, xenograft mice | [83] |
| GV5 (anti-variant 8-epitope of CD44R1) | Human recombinant IgG1 mAb | Uterine cervix and larynx CSCs | Preclinical, xenograft mice | [84] |
| RO5429083 (anti-CD44; targets a glycosylated, conformation-dependent epitope of CD44) | Humanized recombinant IgG1 mAb | Head and neck squamous cell carcinoma | Preclinical, xenograft mice | [86] |
| | | | Patients with metastatic and/or locally advanced, CD44-expressing malignant solid tumors | Phase I clinical study | [88] |
| | | | Patients with AML | Phase I clinical study; RO5429083 alone or in combination with cytarabine | [89] |
| B6H12.2 (anti-CD47, blocking) | Mouse IgG1 mAb | AML SCs, bladder CSCs, glioblastoma CSCs, colon CSCs | Preclinical, xenograft mice | [100] |
| | | | Ovarian, breast, colon, bladder, prostate, hepatocellular, lung, kidney and gastric carcinomas, head and neck squamous cell carcinoma, sarcomas and glioblastomas | Preclinical, xenograft mice | [100] |
| | | | Non-Hodgkin lymphoma, acute lymphoblastic leukemia, multiple myeloma | Preclinical, xenograft mice | [97] |
| | | | | Preclinical, xenograft mice | [101] |
| 7G3 (anti-CD123) | Mouse IgG2a mAb | AML SCs | Preclinical, xenograft mice | [100] |
| | | | Aggressive metastatic leiomyosarcoma | Preclinical, xenograft mice | [107] |
| CSL360 (anti-CD123) | Humanized recombinant chimeric IgG1 mAb | Patients with relapsed, refractory or high risk AML | Phase I clinical study | [113] |
| CSL362 (anti-CD123) | Humanized recombinant chimeric IgG1 mAb | Patients with AML in remission | Phase I clinical study | [114] |
| Fusion of anti-CD123 scFv and anti-CD3 scFv | BITE; human recombinant bispecific mAb construct. | AML blasts and AML SCs | Preclinical, in vitro | [115] |
| Fusion of anti-CD123 scFv, anti-CD3 scFv and anti-CD16 scFv | | | | |
| MT110 (Solitomab) (anti-EpCAM/anti-CD3) | BITE; human recombinant single-chain bispecific bifunctional mAb construct | Breast CSCs, liver CSCs, colon CSCs, pancreatic CSCs | Preclinical, xenograft mice. | [128] |
| | | | Phase I clinical study, advanced solid tumors | [129] |
| Catumaxomab (Removab) (anti-EpCAM/anti-CD3/Fcγ) | Triomab; recombinant chimeric two half antibody, each with one light and one heavy chain from mouse IgG2a and rat IgG2b isotypes. Bispecific, trifunctional mAb construct | CSCs in malignant ascites from metastatic human ovarian, gastric and pancreatic cancers. | Phase I-III clinical studies, malignant pleural effusions, malignant ascites, peritoneal carcinomatosis, Non-small cell lung cancer, ovarian, gastric and epithelial cancer, intraperitoneal administration. | [139] |
| | | | Phase I clinical studies, lung cancer, epithelial cancers, intravenous administration | [140] |
| AVE1642 (anti-IGF-IR) | Humanized recombinant IgG1 mAb, derived from mouse anti-IGF-IR IgG1mAb EM164 | Myeloma cell lines colon CSCs. | Preclinical, in vitro, xenograft mice. | [159] |
| | | | Patients with relapsed multiple myeloma and advanced solid tumors | Phase I clinical study, relapsed multiple myeloma, advanced solid tumors | [157] |

Citation: Naujokat C (2012) Targeting Human Cancer Stem Cells with Monoclonal Antibodies. J Clin Cell Immunol S5:007. doi:10.4172/2155-9899. S5-007
Resistance of CSCs to Novel Tumor-Targeted Drugs

Similar to conventional anticancer drugs, numerous novel tumor-targeted drugs were designed to target rapidly proliferating cancer cells, so that CSCs might be relatively insensitive to these drugs. For instance, imatinib has been developed as an inhibitor of the Bcr-Abl tyrosine kinase, which constitutes the fusion protein product of a chromosomal translocation (so called Philadelphia chromosome) that acts as a molecular switch for proliferation and differentiation of multipotent progenitor cells in chronic myeloid leukemia (CML) [29]. Imatinib has been shown to eliminate proliferating, committed leukemia progenitors, but not nonproliferating CML stem cells [30–33], which persist after imatinib therapy [21], and, after initial therapeutic success, many CML patients become resistant to imatinib therapy [33].

Furthermore, trastuzumab, a humanized monoclonal antibody directed against HER2 has been developed to treat patients with HER2-overexpressing breast cancers that represent one fourth of all breast cancer patients [34]. HER2 is a member of the human epidermal growth factor receptor tyrosine kinase family that is preferentially expressed in breast and ovarian cancer and that activates signaling pathways that promote tumorigenic cellular processes, such as proliferation and evasion of apoptosis [35,36]. However, trastuzumab mono-therapy in patients with HER2-overexpressing metastatic breast cancer shows a response rate of no more than 30 % [37], and primary or acquired resistance to trastuzumab occurs frequently in different clinical settings even when combination regimes are used [34,38,39]. One important mechanism of trastuzumab resistance in the therapy of HER2-overexpressing breast cancer might be the failure of trastuzumab to target breast CSCs [20,22,23,40]. Trastuzumab has been shown to exert its antitumor activities only effectively in the presence of a normal PI3K signaling pathway and in the presence of PTEN [41–44], but CSCs display aberrant PI3K signaling and loss of PTEN [45]. A similar scenario has been reported for the small molecule dual inhibitor of EGFR tyrosine kinase and HER2 tyrosine kinase, lapatinib, which loses its therapeutic activity in breast cancers displaying loss of PTEN [46].

Finally, sorafenib, a small molecule inhibitor of multiple tyrosine kinases involved in tumor proliferation and tumor angiogenesis, including Raf, VEGFR, PDGFR and FLT3 [47] has been established in the treatment of acute myeloid leukemia (AML), because FMS-like tyrosine kinase 3 (FLT3) is overexpressed in leukemic blasts in almost all cases of AML [48]. As demonstrated recently, sorafenib is capable of reducing the number of mature AML progenitors, but fails to eradicate AML stem and primitive progenitor cells due to robust protection of these cells by the bone marrow stromal microenvironment [24], providing a further paradigm that novel tumor-targeted drugs fail to eliminate CSCs.

The Challenge of Targeting CSCs and their Progeny

According to the CSC concept of carcinogenesis [1–10], CSCs represent novel and translationally relevant targets for cancer therapy, and the identification, development and therapeutic use of compounds and drugs that selectively target CSCs is a major challenge for future cancer treatment [5,15,49]. However, the goal for any CSC-directed therapy should be the eradication of all CSCs in a patient, and the efficacy of single agents targeting CSCs may be limited by several factors. CSCs can represent a heterogenous population that may not be homogeneously sensitive to a given anti-CSC agent [9,50], and, under the selection pressure of agents targeting CSCs, therapy resistant CSC clones may emerge [51]. Therefore, the eradication of all CSCs will likely require targeting of more than one intrinsic pathway operating in CSCs to reduce the probability of escape mutants [15]. Moreover, agents causing tumor regression in advanced stages of cancer likely reflect effects on the bulk tumor population, but may have minimal effect on the CSC population. In contrast, a CSC-specific therapy would show modest effect on tumor growth of the bulk tumor population in advanced stages of cancer, but may have substantial clinical benefit in early stages of cancer as well as in neoadjuvant and adjuvant clinical settings [52]. Ultimately, cure of cancer will require the eradication of all malignant cells within a patient’s cancer: CSCs and their progeny. Therefore it will be important and promising to combine in sophisticated clinical settings CSC targeting mAbs with novel tumor-targeted drugs and conventional cytotoxic drugs. Such combinations
may act in concert to eradicate CSCs, differentiated progenitors and bulk tumor cells in cancer patients [53].

Compounds and Drugs that Target CSCs

Various compounds and drugs that selectively target CSCs have been discovered recently [53]. These agents include microbial-derived and plant-derived biomolecules [16,54,55], small molecule inhibitors targeting key components of intrinsic signaling pathways of CSCs, some classical drugs, such as metformin, tranilast and thioridazine [53], and mAbs and antibody constructs directed against CSC-specific cell surface molecules [27,56].

Although these compounds, including mAbs and antibody constructs, have been shown to effectively target signaling pathways and/or molecules selectively operating in CSCs, some of them are also capable of killing other types and subpopulations of cancer cells, which do not display CSC properties. Finally, recent data obtained in xenograft mice with human cancers indicate that mAbs and antibody constructs targeting CSCs are most effective in eradicating CSCs and their progeny when these agents are combined with conventional cytostatic drugs [57-63], envisioning the use of complex combination therapies for the future treatment of cancer.

Antibodies against CSC Surface Molecules, Tested for Anti-CSC Activity

These mAbs and antibody constructs have been demonstrated to exhibit significant anti-CSC activity in vitro and in human xenograft mice (Table 1).

Anti-CD44

CD44 is a transmembrane glycoprotein and the receptor for hyaloronic acid, osteopentin, collagens, fbronectin, selectin and laminin that mediates adhesive cell to cell and cell to extracellular matrix interactions through binding to hyaloronic acid and its other ligands [64]. Overexpression of CD44 is observed in many tumor cells and is associated with aggressive tumor growth, invasion and metastasis [65]. CD44 was first described as a CSC marker in breast cancer [66] and has subsequently been shown to be expressed on CSCs in bladder, gastric, prostate, pancreatic, ovarian, colorectal and hepatocellular carcinomas and head and neck squamous cell carcinomas [67]. CD44 plays an important role in the regulation of normal and malignant myelopoiesis and is abundantly expressed on leukemic blasts in all human acute myeloid leukemia (AML) subtypes and on AML CSCs [27,68-70]. Moreover, a number of recent studies suggest that CD44 fulfills some of the special properties that are displayed by CSCs, including self-renewal, niche preparation, EMT and resistance to apoptosis [71]. Therefore, targeting CD44 by monoclonal antibodies appears as a reasonable strategy to eliminate CSCs [27,72].

H90 is a mouse IgG1 monoclonal antibody (mAb) directed against human CD44 [73]. Ligation of CD44 by H90 activates CD44 signaling, reverses myeloid differentiation blockage and induces myeloid differentiation in AML blasts of subtypes M1 to M5 obtained from different patients [74]. H90 also inhibits proliferation, induces terminal differentiation and mediates apoptosis in human myeloid leukemia cell lines [75,76]. Notably, H90 is the first mAb that has been shown to target CSCs. As demonstrated in a seminal study in 2006, H90 induces terminal differentiation and inhibits engraftment, homing, proliferation and the repopulation capacity of human AML SCs in NOD-SCID mice engrafted with CD34+ CD38- AML SCs isolated from AML patients [70]. By contrast, H90 treatment of NOD-SCID mice engrafted with human bone marrow CD34+ hematopoietic progenitor cells or cord blood had only a minor effect on inhibition of normal hematopoietic engraftment, indicating the specificity of H90 for AML SCs [70]. Collectively, this study reveals for the first time that CD44 is a key regulator of AML SC function that is essential for proper homing of AML SCs to microenvironmental niches and for maintaining AML SCs in a primitive state [70].

Another mouse IgG1 mAb raised against human CD44 is P245, which has been shown to reduce tumor growth and to eliminate breast CSCs in xenograft mice with human triple negative basal-like breast cancer [77]. Triple-negative (negative expression of estrogen receptor, progesterone receptor, and HER2) basal-like breast cancer cells resemble many features of breast CSCs, including expression of CD44high, CD24low and ALDH-1. The triple negative basal-like subtype of breast cancer is characterized by a high content of breast CSCs, aggressive proliferation, high metastatic capability and poor overall survival of patients [78-81]. P245 has been shown to significantly reduce tumor growth in xenograft mice with human triple negative basal-like breast cancer [77]. Treatment of the mice with doxorubicin and cyclophosphamide, a cytostatic drug combination commonly used for the therapy of triple negative basal-like breast cancer, resulted in complete histological tumor regression, but residual breast CSCs survived the doxorubicin/cyclophosphamide therapy and could be detected by virtue of their CD44 expression [77]. Tumor relapse mediated by the residual CD44 breast CSCs occurred 4-6 weeks after complete histological regression, but the relapse could be effectively prevented when P245 was systemically injected during the tumor regression period [77]. These data provide substantial evidence that anti-CD44 mAbs such as P245 can eliminate human breast CSCs and can prevent relapse of aggressive breast cancer.

H4C4 is a mouse IgG1 mAb that recognizes a constant region of the human CD44 receptor. The antibody was originally developed against human peripheral blood adherent cells and displayed the property of inducing in vitro homotypic aggregation of several types of human hematopoietic cells and cell lines [82]. Recently, it was demonstrated that H4C4 markedly decreases tumorsphere formation of human pancreatic cancer stem-like cells in vitro and inhibits human pancreatic tumor growth, metastasis and tumor recurrence in xenograft mice [83]. In particular, pretreatment of human MiaPaCa-2 pancreatic cancer cells with H4C4 dramatically decreased tumorsphere formation of CD44- MiaPaCa-2 cells and totally blocked tumorigenesis after implantation of the cells into nude mice. In xenograft mice bearing orthotopic human pancreatic cancer established by implantation of MiaPaCa-2 cells, treatment with H4C4 for 5 weeks resulted in significant inhibition of tumor growth and metastasis as well as in inhibition of tumor recurrence after tumor elimination by radiation therapy with a total dose of 24 Gy. Finally, mechanistic experiments in vitro revealed that H4C4 inhibits CD44-STAT3 signaling pathways that is accompanied by the elimination of the pancreatic cancer stem-like cells [83].

A recombinant fully human IgG1 mAb recognizing the extracellular domain of an alternative splicing variant of CD44, CD44R1(v8-v10), was produced recently by genetic reshaping and class-switching from a human CD44R1-detecting IgM to a recombinant human CD44R1-detecting IgG1, termed GV5 [84]. GV5 showed preferential binding to the CD44R(v8-v10) isoform, which is overexpressed in colorectal, bladder, lung and larynx cancers as well as in basal-like breast cancers resembling breast CSCs [84,85]. In a xenograft mouse models, GV5 completely inhibited tumorigenesis and tumor formation of human ME180 uterine cervix carcinoma cells subcutaneously implanted with...
orthotopic GV5 administration. Moreover, intraperitoneal injections of GV5 markedly inhibited the growth of established tumors from human HSC-3 larynx carcinoma cells implanted into xenograft mice one week before the first GV5 treatment [85]. Results from in vitro experiments presented in the study strongly suggest that GV5 exerts its anti-tumor activity by induction of antibody-dependent cellular cytotoxicity (ADCC) and internalization of CD4R1 [84].

ROS429083 is a novel functional recombinant humanized IgG1 mAb that targets a glycosylated, conformation-dependent extracellular epitope of human CD44 [85]. The antibody has recently been shown to markedly inhibit tumor growth in xenograft mice with human head and neck squamous cell carcinomas (HNSCC) induced by human CAL 27 HNSCC cells, whereas cisplatin, a cytostatic drug clinically used for HNSCC treatment, showed only a little effect on tumor growth inhibition [85]. Moreover, treatment of xenograft mice with ROS429083 inhibited constitutive epithelial growth factor receptor (EGFR) phosphorylation in CAL 27 HNSCC xenografts [85]. This is of considerable clinical importance because constitutive EGFR phosphorylation has been shown to be associated with early relapse and poor prognosis in patients with HNSCC [86,87]. Finally, ROS429083 treatment of peripheral mononuclear cells isolated from healthy human donors resulted in an expansion of cytolytic natural killer (NK) cells, demonstrating that ROS429083 is able to activate effector cells of the innate immune system [86]. These promising preclinical results have very recently led to the initiation of two phase I clinical studies: a study of ROS429083 in patients with metastatic and/or locally advanced, CD44-expressing, malignant solid tumors [88], and a study of ROS429083 alone or in combination with cytarabine in patients with acute myelogenous leukemia [89].

**Anti-CD47**

CD47 is a widely expressed transmembrane protein and a receptor for thrombospondin family members that also serves as the ligand for the signal regulatory protein alpha (SIRPα) [90-92]. SIRPα is expressed on phagocytic cells, including macrophages and dendritic cells that when bound and activated by CD47 initiates a signal transduction cascade resulting in inhibition of phagocytosis [91,93,94]. Therefore, the CD47/SIRPα interaction has been attributed as a mechanism that provides a "don’t eat me"-signal [95]. Abundant expression of CD47 is exploited by tumor cells to avoid phagocytosis by tumor-associated macrophages and is required for survival, growth and metastasis of hematopoietic and solid tumors [96-100].

A seminal study revealed that CD47 is abundantly expressed on human AML SCs and that CD47 is much more highly expressed on AML SCs than on their normal counterparts, such as hematopoietic stem cells (HSCs) and multipotent progenitor cells [101]. As investigated in a large cohort of AML patients, increased CD47 expression in human AML is associated with poor clinical outcome and worse overall survival, providing evidence that increased CD47 expression on AML SCs substantially contributes to the pathogenesis and fate of human AML [101]. It was shown in the study that the CD47-binding and CD47-blocking mouse IgG1 mAb B6H12.2 preferentially enables phagocytosis of human AML SCs by human and mouse macrophages in vitro, whereas non-blocking anti-CD47 mAbs failed to enable phagocytosis of the AML SCs by human and mouse macrophages [101]. Similar results were obtained in a study using a blocking anti-CD47 mAb and human bladder CSCs highly expressing CD47 [102]. Further, in a xenograft mouse model, B6H12.2 prevented the engraftment of human AML SCs, and treatment of human AML xenograft mice with B6H12.2 completely eradicated AML cells by the mechanism of phagocytosis in vivo, whereas normal HSCs were not depleted [101]. Thus, human AML SCs can be targeted and eradicated with blocking anti-CD47 antibodies such as B6H12.2 capable of enabling phagocytosis of AML SCs.

A recent comprehensive study impressively shows that CD47 is highly expressed on virtually all human solid tumor cells, as demonstrated in ovarian, breast, colon, bladder, prostate, hepatocellular, lung, kidney and gastric carcinomas, sarcomas and glioblastomas obtained from patients [100]. The study further demonstrates that anti-CD47 blocking mAb B6H12.2 enables phagocytosis of patient-derived ovarian, breast and colon carcinoma cells as well as of glioblastoma CSCs and colon CSCs by mouse and human macrophages *in vitro*. Administration of B6H12.2 prevented and inhibited tumor growth in xenograft mice with patient-derived glioblastoma and ovarian, breast, colon and bladder cancer, and increased the survival of the xenograft mice over time. In xenograft mice transplanted with aggressive and spontaneously metastasizing patient-derived bladder cancer and head and neck squamous cell carcinoma, administration of B6H12.2 effectively prevented lung and lymph node metastases and also induced a significant inhibition of primary site tumor growth [100]. This study was extended to examine the effect of anti-CD47 B6H12.2 on human hematopoietic malignancies. In xenograft mice with human non-Hodgkin lymphoma [103], acute lymphoblastic leukemia [104] and multiple myeloma [105], B6H12.2 was able to inhibit tumor growth and dissemination by the mechanism of blocking the CD47-SIRPα interaction and enabling phagocytosis of CD47-expressing tumor cells. Interestingly, B6H12.2 did not induce ADCC or complement-dependent cytotoxicity (CDC) and exerted its anti-tumor activity exclusively by promoting phagocytosis of CD47-expressing tumor cells [97,105].

Finally, a fully humanized blocking anti-CD47 mAb (B6H12) [106] has recently been shown to effectively inhibit tumor growth and metastasis in xenograft mice with human aggressive metastatic leiomyosarcoma [107]. These results collectively indicate that all human solid and hematopoietic tumor cells require CD47 expression to suppress phagocytic innate immune surveillance and elimination, and that blockade of CD47 function by anti-CD47 mAbs such as B6H12.2 and B6H12 represents a novel and effective strategy for cancer therapy.

**Anti-CD123**

The mouse IgG2a mAb 7G3 recognizes the N-terminal domain of the human interleukin-3 (IL-3) receptor α chain (CD123) and functions as a specific IL-3 receptor antagonist that antagonizes IL-3 biologic activities, such as histamine release from basophil granulocytes or IL-6 and IL-8 secretion from endothelial cells [108]. In comparison to normal hematopoietic stem cells (HSCs), CD123 is overexpressed on AML blasts, CD34+ leukemic progenitors and AML SCs, and confers growth advantage of AML cells over HSCs [109-111]. Clinically, high CD123 expression in AML is associated with higher blast counts at diagnosis and a lower complete remission rate that results in poor prognosis and reduced survival [110,112], ultimately defining CD123 as a promising cell-surface target for the elimination of AML SCs and the eradication of AML.

In fact, the CD123-targeting antibody 7G3 has been shown to eliminate human AML SCs [111]. *Ex vivo* treatment of primary human AML cells with 7G3 selectively inhibited engraftment, repopulation ability, and bone marrow and spleen homing of the cells in NOD/SCID mice, whereas 7G3 treatment of normal HSCs derived from human cord blood or bone marrow resulted in significant engraftment.
and hematopoietic differentiation of the human HSCs in NOD/SCID mice. Moreover, 7G3 selectively eradicated human AML SCs in NOD/SCID mice engrafted with primary human AML cells. It was further demonstrated that 7G3-mediated inhibition of engraftment and homing of AML SCs in NOD/SCID mice is dependent on ADCC induced by the Fc fragment of 7G3, and that 7G3 inhibits spontaneous and IL-3-induced proliferation of AML SCs in vitro. These pleiotropic activities of 7G3 against human AML cells and AML SCs finally led to the reduction of AML burden and to an improved long-term survival of NOD/SCID mice engrafted with human AML [111].

CSL360 is a recombinant chimeric IgG1 mAb derived from 7G3 that binds to the same epitope of the (IL-3) receptor a chain (CD123) as 7G3. In a phase I clinical study, 40 patients with relapsed, refractory or high-risk AML received 12 weekly intravenous infusions of CSL360 at dose levels from 0.1 to 10 mg/kg [113]. CSL360 treatment with a dose of ≥ 3 mg/kg resulted in sustained saturation and down-regulation of CD123 on AML blasts as well as in inhibition of ex vivo proliferative responsiveness of AML blast to IL-3. However, changes of the percentage of AML SCs in the patients’ bone marrow were not observed during the study. Only one patient became leukemia-free and achieved a complete remission after 12 doses, indicating that CSL360 has no significant anti-leukemic activity in high-risk AML patients, and suggesting that blockade of IL-3 signaling is an ineffectual therapeutic strategy for these patients [113]. Nevertheless, a phase I study of CSL362, a second generation mAb targeting the IL-3 receptor a chain, in patients with CD123+ acute myeloid leukemia in remission, has been started in September 2012 [114].

Some novel and interesting antibody constructs targeting CD123 and CD3 (bispecific antibody) or CD123, CD33 and CD16 (Fcγ-receptor III) (trispecific antibody) have been generated recently. The bispecific antibody constructs belong to the bispecific T cell engager (BiTE) class of antibodies and consist of a single chain variable region fragment (scFv) targeting CD123 and a scFv targeting the T cell receptor protein complex CD3. When expressed from CHO-S cells, CD123 scFv and CD3 scFv form a homodimer that closely resembles the structure of a natural antibody. This bispecific antibody construct is capable of redirecting and activating resting T cells (CD3+CD5+) via its CD3 scFv and simultaneously binding to CD123, thereby inducing T-cell mediated lysis and apoptosis of CD123+ AML blasts and AML SCs [115]. The trispecific constructs consist of scFvs binding to CD123, CD33 and CD16, and are able to target CD123/CD33 AML blasts and to mediate ADCC via binding of the Fcγ-receptor III (CD16) expressed on macrophages and NK cells. These antibody constructs have recently been shown to induce potent ADCC of primary leukemia cells isolated from peripheral blood or bone marrow of AML patients [116].

Finally, the anti-CD123 mAb 7G3 has recently been used for the generation of an Auger electron radioimmunotherapeutic agent for targeting CD123+ AML SCs. The antibody was modified with 13-mer peptides harboring the nuclear translocation sequence (NLS) of SV-40 large T-antigen and with the chelating agent DTPA for labelling with the Auger electron-emitting isotope 125IIndium [117]. This radioimmunonuherapeutic agent, termed 111In-NLS-7G3, binds effectively to primary CD123+ AML cells from patients and is rapidly imported into the nucleus where it induces DNA double-strand breaks leading to apoptosis. As demonstrated in xenograft mice with human CD123+ AML, 111In-NLS-7G3 can also be used for highly sensitive imaging of CD123+ AML cells or AML SCs in SPECT/CT [117].

Anti-EpCAM

EpCAM (epithelial cell adhesion molecule, CD332, ESA) is an integral transmembrane glycoprotein composed of a large extracellular domain, one transmembrane region, and a small 26 amino acid intracellular domain. Beyond its adhesion function, EpCAM can transduce multiple oncogenic signaling and gene expression pathways to the nucleus after regulated intramembrane proteolysis of its ectodomain and subsequent nuclear translocation of its intracellular domain [118]. Overexpression of EpCAM in combination with CD44 was first demonstrated for CSCs in human breast carcinomas [66], colorectal carcinomas [119], and pancreatic carcinomas [120], and can be regarded as a universal marker exclusively expressed by epithelial cancers and their CSCs [121-123].

MT110 (Solitomab) is bispecific bifunctional single-chain antibody construct of the BiTE class that binds to EpCAM (CD326) and to the T cell receptor protein complex CD3 [124]. MT110 is a recombinant protein construct that consists of 2 single-chain antibodies linked such that a single polypeptide chain of approximately 55 kDa is created. In contrast to bispecific trifunctional antibody constructs (Triomabs), MT110 and other BiTE class antibodies lack an Fcγ portion [125]. MT110 activates and redirects resting human peripheral CD4+ and CD8+ T cells to induce specific lysis and apoptosis of target cells expressing EpCAM [124-127]. Initially, it was demonstrated that MT110 is able to eradicate human colon cancer cells and patient-derived metastatic ovarian cancer in NOD/SCID xenograft mice [124]. Moreover, ex vivo treatment with MT110 of malignant pleural effusions obtained from patients with advanced breast cancer resulted in a specific lysis of pleural EpCAM+ breast cancer cells by activated and redirected autologous CD4+ and CD8+ T cells, indicating that breast cancer patients with malignant pleural effusions might benefit from targeted therapy with MT110 [126]. Next, EpCAM-expressing CSCs derived from human liver and breast cancer tissues could be eradicated in soft agar colonies by MT110 in the presence of human T cells [128]. CSCs isolated from patient-derived primary colon or pancreatic cancers injected together with allogeneic or autologous (donor-derived) peripheral mononuclear cells into NOD/SCID mice were effectively eradicated by MT110, and the CSCs did not establish significant tumor growth in the NOD/SCID xenograft mice treated with MT110 [129,130]. These promising results suggest that EpCAM-expressing CSCs and cancer cells can effectively be eradicated by MT110. Consequently, a phase I clinical study of MT110 in patients with locally advanced, recurrent or metastatic solid tumors expressing EpCAM has been initiated in 2008 and is ongoing and recruiting participants [131]. Interim results from this study have been reported recently. Sixteen patients who received a dose of ≥ 24 μg/day MT110 were evaluable for anti-tumor response: best response of stable disease was observed in 38% of the patients, median duration was 155 days [132], pointing out an encouraging anti-tumor activity of MT110 in patients with advanced solid tumors.

Catumaxomab (Removab) is a chimeric antibody construct consisting of two half antibodies, each with one light and one heavy chain that originate from parental mouse IgG2a and rat IgG2b isotypes [133]. This antibody construct belongs to a novel family of bispecific, trifunctional antibodies termed Triomabs, and has two binding specificities directed against EpCAM and one against the T cell receptor protein complex CD3. With its Fc fragment, catumaxomab additionally binds Fcγ-receptor type I and III positive dendritic cells, macrophages and natural killer cells. Therefore, the anti-tumor activity of catumaxomab and other Triomabs such as Ektomun (see below) results from T-cell-mediated lysis and apoptosis induction.
ADCC, and phagocytosis via activation of Fcy-receptor-positive accessory cells. Importantly, no additional activation of immune cells is necessary for effective tumor elimination by catumaxomab, which therefore represents a self-supporting system [134,135]. In contrast to mAbs of the BITE class, Triomabs exert a vaccination effect and induce long-lasting antitumor immunity, most likely due to their Fc-mediated interaction with Fcy-receptors expressed on dendritic cells and macrophages [136-138].

Catumaxomab has recently been shown to induce regression of malignant pleural effusions, malignant ascites and peritoneal carcinomatosis in patients with advanced epithelial cancers resistant to conventional chemotherapy [139-141]. In addition, catumaxomab is able to effectively eliminate CD133+/EpCAM+ CSCs from malignant ascites of patients with advanced ovarian, gastric and pancreatic cancer [142], indicating that catumaxomab can be therapeutically used to eradicate CSCs of epithelial cancers. Therefore, catumaxomab is currently in phase I-III clinical studies for local therapy in patients with advanced ovarian, gastric and non-small cell lung cancer, and is in the European Union on the market for the therapy for the malignant ascites caused by epithelial cancers [143]. In a phase I clinical study of a single intravenous dose of catumaxomab at 3 dose levels (2 μg, 5 μg, and 7.5 μg) in 15 patients with advanced non-small cell lung cancer, catumaxomab exhibited considerable antitumor activity and favourable overall survival as well as low general toxicity and only transient elevation of liver enzyme levels (AST, ALT, and γGT) [144]. A phase I clinical study of ascending intravenous doses of catumaxomab in patients with EpCAM-overexpressing epithelial cancers has been initiated in 2011 and is ongoing and recruiting participants [145].

Other anti-EpCAM antibodies, including edrecolomab (Panorex®, mouse IgG2a mAb) and adecatumumab (MT201, a recombinant fully human IgG1 mAb) [146-148] have been tested in clinical studies, but have not yet been investigated for their activity against CSCs.

Anti-insulin-like growth factor receptor I (anti-IGF-IR)

Insulin-like growth factors (IGFs) constitute polypeptide hormones with anabolic and mitogenic activities that regulate cell growth and differentiation. Deregulation of IGF signaling has been widely demonstrated in the development and progression of multiple types of human cancer, consequently leading to the development and validation of therapeutics that target IGF signaling [149,150]. Various humanized recombinant mAbs targeting the insulin-like growth factor receptor I (anti-IGF-IR), a transmembrane tyrosin kinase receptor for IGF-I and IGF-II that is overexpressed in many cancers [151,152], have been developed and tested in phase I-III clinical studies, alone or in combination with conventional cytostatic drugs and novel tumor-targeted drugs [150]. Although some IGF-IR-targeting mAbs, including figitumumab (CP-751.871), cixutumumab (IMC-A12), dalotuzumab (MK-0646), ganitumab (AMG-479), BI2022 and AVE1642 showed rather disappointing results in clinical studies [150,153-156], AVE1642 and figitumumab have recently been demonstrated to target human colon CSCs in vitro and in xenograft mice [157,158].

AVE1642 is a humanized recombinant IgG1 mAb derived from mouse anti-IGF-IR IgG1 mAb EM164. AVE1642 inhibits growth and increases bortezomib-induced apoptosis of aggressive human myeloma cells in vitro [159]. Based on these results, a phase I clinical study of AVE1642 in combination with the proteasome inhibitor bortezomib was conducted in patients with relapsed multiple myeloma. Despite the favorable toxicity profile of the antibody, the response rates for patients treated with AVE1642 alone or in combination with bortezomib were considered insufficient to merit further development of AVE1642 in multiple myeloma [153]. However, AVE1642 has been shown to inhibit IGF-IR signaling and proliferation of colon CSCs enriched from the human colon cancer cell line HT29. Moreover, the antibody was able to induce significant regression of tumors established by the colon CSCs in xenograft mice [157], indicating a potential of AV1642 to eradicate colon CSCs.

Figitumumab (CP-751,871) is a fully human IgG2 mAb against the IGF-IR that have been tested in phase I-III clinical trials in patients with non-small cell lung cancer and other solid tumors with a rather disappointing outcome, leading to the discontinuation of two phase III trials due to insufficient clinical activity of the antibody [150,160-162]. Despite its rather weak antitumor activity in human solid tumors, figitumumab inhibited IGF-IR signaling, IGF-IR induced Akt activation and growth of colon CSCs with enhanced IGF signaling that were enriched from human colon cancer cell lines [158]. Figitumumab also markedly inhibited growth of tumors established by the human colon CSCs in xenograft mice [158]. These results emphasize that IGF-IR targeting with mAbs may be used for the eradication of CSCs displaying deregulated IGF signaling, as demonstrated hitherto for human colon CSCs.

Anti-delta-like 4 ligand (anti-Dll4)

The Notch pathway is an evolutionary conserved signaling system that regulates cell fate specification, tissue patterning and morphogenesis by modulating cell differentiation, survival, proliferation and apoptosis. In mammals, the system consists of five canonical ligands, Delta-like (Dll) 1, 3, 4, Jagged 1, 2, and four single-pass transmembrane receptors, Notch 1-4 [163]. Aberrant Notch signaling has been implicated in promoting tumorigenesis and has been shown to critically regulate self-renewal, survival and multiresistance of CSCs [164,165]. Overexpression of Dll4 is found in tumor vasculature and in tumor cells to activate Notch signaling [166], and blockade of Dll4 signaling in tumors results in excessive, non-productive tumor vascularity, paradoxically associated with poor tumor perfusion, hypoxia and decreased tumor growth [167,168].

A humanized recombinant IgG mAb (OMP-21M18, demizumab) that blocks Dll4 was shown to have anti-tumor activity independent of an angiogenic mechanism in xenograft mice with patient-derived colon and breast cancers [57]. Moreover, OMP-21M18 was able to reduce the frequency of CSCs in colon and breast tumors in vitro and in vivo, the latter was demonstrated in explanted tumors of xenograft mice treated with OMP-21M18. The combination of OMP-21M18 with the cytostatic drugs irinotecan and paclitaxel significantly reduced the frequency of colon CSCs and breast CSCs, respectively. This was observed in vitro and in explanted colon and breast tumors of xenograft mice treated with the antibody and the respective cytostatic drug [57]. OMP-21M18 also exhibited strong anti-tumor activity in patient-derived colon cancers with oncogenic KRAS mutations that are intrinsically resistant to epidermal growth factor receptor (EGFR) blockade with the mAb cetuximab [58]. In xenograft mice with patient-derived mutant KRAS colon cancers, OMP-21M18 was able to significantly reduce tumor growth that was further enhanced when OMP-21M18 was combined with irinotecan. Further analysis of mutant KRAS tumors explanted from xenograft mice indicated that OMP-21M18 in combination with irinotecan produced a significant decrease in colon CSC frequency while promoting apoptosis in tumor cells [58]. Similar results were obtained recently with OMP-21M18 alone and OMP-21M18 combined with the cytostatic drug gemcitabine in xenograft mice with patient-derived pancreatic cancer [59]. Furthermore, recent studies indicate that OMP-21M18 is able to inhibit tumor growth, recurrence and metastases, and to reduce the frequency of CSCs in xenograft mice.
with patient-derived melanomas [169]. Even in xenograft mice with B-RAF V600E melanomas resistant to B-Raf inhibitors, OMP-21M18 was able to significantly reduce tumor growth and the frequency of melanoma CSCs [170]. In xenograft mice with patient-derived triple-negative breast cancer, which constitutes a progesterone-receptor-negative, estrogen-receptor-negative and HER2-negative aggressive subtype of human breast cancer containing high contents of CSCs [81], OMP-21M18 and OMP-21M18 combined with paclitaxel targets the tumor vasculature, inhibits tumor growth, delays tumor recurrence, and decreases the frequency of CSCs [60]. Finally, a recent study demonstrates that OMP-21M18 delays tumor recurrence, overcomes drug resistance, inhibits EMT, and decreases the frequency of CSCs in xenograft mice with patient-derived breast cancer and pancreatic cancer [171]. All these promising results from preclinical studies in xenograft mice with various patient-derived cancers have recently led to the initiation of phase I/IIb clinical studies of OMP-21M18 in patients with solid tumors [172], metastatic colorectal cancer [173], pancreatic cancer [174] and non-small cell lung cancer (NSCLC) [175].

Another humanized IgG mAb against Dll4 is REGN421, which has been developed on the basis of results of a study with polyclonal anti-mouse Dll4 antibodies exhibiting strong anti-tumor activity and induction of non-productive angiogenesis in mouse tumor models [167]. REGN421 is currently tested in a phase I clinical study in patients with advanced solid tumors [176].

Anti-Frizzled

The Frizzled (FZD) family of transmembrane G protein-coupled receptors consists of 10 members (FZD 1-10), which are activated by secreted lipoglycoproteins of the Wnt family [177]. The highly conserved Wnt/FZD signaling pathway has multiple functions in animal development and cell fate determination and polarization [178]. Deregulation of the Wnt pathway and up-regulation of FZD receptors play important roles in tumorigenesis and CSC maintenance that is observed in a variety of human cancers, including colorectal cancer, hepatocellular carcinoma and triple-negative breast cancer [164,178-181].

OMP-18R5, a humanized recombinant IgG2 mAb binding to a conserved epitope within the extracellular domain of FZD1, FZD2, FZD5, FZD7 and FZD8 has recently been developed. Through binding to FZD receptors, OMP-18R5 blocks Wnt3A-induced phosphorylation of the Wnt co-receptor LPR6 and accumulation of Wnt signaling protein β-catenin, thereby inhibiting canonical Wnt signaling [62]. Importantly, in contrast to the cytostatic drugs gemcitabine and paclitaxel, OMP-18R5 is able to reduce the frequency of CSCs in patient-derived pancreatic and breast carcinomas established in xenograft mice [61-63]. OMP-18R5 alone, and more effectively in combination with cytostatic drugs, inhibits tumor growth of patient-derived colon, breast, lung and pancreatic cancer in xenograft mice [61-63], pointing out that OMP-18R5 should be regarded as promising agent for the elimination of CSCs and the future treatment of solid tumors. Consequently, a phase I dose escalation study of OMP-18R5 in patients with solid tumors has been initiated in 2011 and is still recruiting participants [182].

Antibodies against CSC Surface Molecules, Not Yet Tested for Anti-CSC Activity

These mAbs and antibody constructs bind to cell surface molecules expressed by CSCs, but have not yet been demonstrated to exhibit anti-CSCs activity in vitro and in human xenograft mice (Table 2).

Anti-CDC133

Human CDC133 (prominin-1) is a transmembrane single-chain glycoprotein with two large extracellular loops containing four N-linked glycosylation sites on each extracellular loop, and two small intracellular loops [183,184]. Originally identified as a cell surface antigen present on CD34+ hematopoietic stem cells [183], CD133 has recently been established as marker for the isolation and analysis of CSCs in solid tumors, including breast tumors, and colon, prostate, lung, ovarian, pancreatic and hepatocellular carcinomas [184,185]. CD133 exhibits several splice variants and different poorly characterized glycosylated isoforms, such as CD133-1 and CD133-2, which are bound by the mouse IgG1 mAbs AC133 and AC141, respectively [183,185,186]. Although AC133 has been shown to be unsuitable for the detection of CSCs in glioblastoma, because glioblastoma CSCs can solely express non-glycosylated isoforms of CD133 not detectable by AC133 or AC141 [185,187,188], colon CSCs selectively express a distinct CD133 epitope which is bound by AC133 and which is lost upon colon CSC differentiation [189]. Therefore, AC133 can be used for the selective detection and isolation of colon CSCs, whereas its specificity for the detection of CD133+ CSCs in other solid tumors is uncertain [184,185].

Two mAbs, 32AT1672 (mouse IgG1) and C24B9 (rabbit IgG) that recognize unmodified non-glycosylated epitopes of CD133 are commercially available for research purpose [185]. C24B9 has recently been shown to detect a truncated variant of the CD133 protein expressed by glioblastoma cells that could not be detected by AC133 [187], ultimately indicating that CD133 exhibits numerous variants and epitope modifications detected by different mAb species. Therefore, it is still questionable whether CD133 represents a specific marker for CSCs and a therapeutic target for antibody-mediated elimination of CSCs.

Anti-GD2

Gangliosides represent a family of sialic acid-containing glycosphingolipids that are anchored to the plasma membrane by a lipophilic ceramide segment, with the antigenic hydrophilic carbohydrate section extending extracellularly. Through interactions with carbohydrate-binding proteins on apposing cells, gangliosides function as receptors in cell to cell recognition and also interact laterally in their own membranes to regulate the responsiveness of various signaling proteins [190]. GD2 is a b-series disialoganglioside selectively, but weakly expressed in the fetal and adult central nervous system, umbilical mesenchymal stem cells, peripheral nerves, and skin melanocytes [191,192]. However, GD2 is highly expressed in human tumors of neuroectodermal origin, including neuroblastomas, melanomas, gliomas, small cell lung carcinomas (SCLC), Ewing sarcomas as well as in osteosarcomas and some soft-tissue sarcomas [191]. Recently, it has been shown that GD2 is expressed on highly tumorigenic CSCs isolated and enriched from human breast cancer cell lines or breast cancer patient samples [193], thus identifying GD2 as a putative cell surface target for mAb-mediated eradication of breast CSCs. Because of the relatively selective expression of GD2 on the cell surface of neuroectodermal tumors and breast CSCs, GD2 is an attractive and promising target for tumor-specific antibody therapy. In fact, several mAbs against GD2 have been developed for clinical use and treatment of neuroectodermal tumors over the past two decades [194].

3F8 is a mouse IgG3 mAb raised against human GD2 that has undergone extensive preclinical and clinical testing [191,195]. Initially, it was demonstrated that 3F8 binds with high affinity to GD2 expressed on human melanoma cell lines as well as on human neuroblastoma and osteosarcoma cells from patient samples [195]. The mechanisms of tumor cell killing by 3F8 were shown to be mediated by ADCC and CDC [191,195]. In two clinical studies, one phase I study in patients with neuroblastoma and melanoma [196] and one phase II study in patients with stage IV neuroblastoma [197], intravenous administration of 3F8 displayed manageable toxicity and adverse side effects as well as marked anti-tumor activity. To circumvent human
Table 2: Antibodies and antibody constructs against CSC surface molecules, not yet tested for anti-CSC activity.

| Compound | Class | Targets | Status/Use | References |
|----------|-------|---------|------------|------------|
| AC133, (anti-CD133-1); AC141 (anti-CD133-2) | Mouse IgG1 mAb | Poorly characterized glycosylated CD133 extracellular epitopes of uncertain specificity; colon CSCs | Experimental research, in vitro detection of CD133+ cells [183] |
| 32AT1672 (anti-CD133); C24B9 (anti-CD133) | Mouse IgG1 mAb; rabbit IgG mAb | Unmodified (non-glycosylated) extracellular epitopes of CD133 | Experimental research, in vitro detection of CD133+ glioblastoma cells [185] |
| 3F8 (anti-GD2) | Mouse IgG3 mAb | Human neuroblastoma and osteosarcoma samples and melanoma cell lines; patients with advanced neuroblastoma and melanoma | Phase I and II clinical studies in patients with neuroblastoma and melanoma [195] |
| Hu3F8 (anti-GD2) | Humanized IgG1 and IgG4 mAbs | Human neuroblastoma cells, neuroblastoma xenograft mice; patients with neuroblastoma | Phase I clinical study in patients with high risk neuroblastoma and GD2-positive tumors [198] |
| 3F8BiAb (anti-GD2/anti-GD3) | Heteroconjugate of 3F8 and mouse IgG2a mAb OKT3 | Human neuroblastoma cell lines | Experimental research, in vitro killing of neuroblastoma cells by redirected activated T cells [200] |
| Ch14.18 (anti-GD2) | Chimeric mAb: Fab of mouse anti-GD2 IgG2a mAb 14G2, fused with human Fc constant IgG1 regions | Patients with melanoma and high-risk neuroblastoma | Phase I clinical studies in patients with neuroblastoma and melanoma; phase III clinical studies; identification of cytokines and cytostatic drugs in neuroblastoma patients [202] |
| TRBs07, Ektomun, Ektomab (anti-GD2 and anti-GD3/anti-CD3/Fcy) | Triomab; recombinant chimeric two half antibody, each with one light and one heavy chain from mouse IgG2a (Me361) and rat IgG2b (26II6) isotypes. Bispecific, trifunctional mAb construct | Human melanoma cell lines; mouse melanoma model treated with Triomab Surek (anti-mouse-CD3/anti-GD2, anti-GD3/Fcy) | Experimental research, in vitro killing of melanoma cells by redirected activated T cells; induction of tumor eradication and tumor immunity in a mouse melanoma model by Surek [209] |
| KM4056 (anti-Lgr5) | Rat IgG2b mAb | CHO cells expressing the human CSC-marker Lgr5 | Preclinical, xenograft mice [217] |
| 1D9, 4D11, 9G5 (anti-Lgr5) | Rat IgG mAbs | Colon CSCs isolated and enriched from patient-derived colorectal cancers | Preclinical, In vitro, xenograft mice, identification of colon CSCs [218] |

anti-mouse antibody response against 3F8 and to enhance the ADCC properties of 3F8, humanization of 3F8 was performed, and humanized recombinant IgG1 and IgG4 mAbs (Hu3F8-IgG1 and Hu3F8-IgG4) were produced [198]. Hu3F8-IgG1 was intensively tested in vitro, and displayed more potent ADCC mediated by both peripheral blood mononuclear cells and polymorphonuclear leucocytes than 3F8. Moreover, Hu3F8-IgG1 was able to induce a stronger anti-tumor effect in human neuroblastoma xenograft mice than 3F8 [198]. This superior therapeutic activity of Hu3F8-IgG1 compared to 3F8 has recently led to the initiation of a phase I clinical study of Hu3F8 in patients with high-risk neuroblastoma and GD2-positive tumors [199]. Further, a bispecific mAb targeting both GD2 and CD3 was generated by chemical heteroconjugation of 3F8 and OKT3 (mouse anti-human CD3ε IgG2a mAb). This bispecific antibody construct, termed 3F8BiAb, redirects and activates non-MHC restricted human peripheral CD3+ T cells to induce specific lysis of target cells expressing GD2, as demonstrated in vitro for various human neuroblastoma cell lines [200].

The human-mouse chimeric anti-GD2 mAB ch14.18 consists of the Fab portion of the mouse anti-GD2 IgG2a mAb 14G2a fused with the human Fc constant regions of an IgG1 immunoglobulin [201]. Ch14.18 retains the anti-GD2 specificity and the ability to target GD2-expressing tumors observed with 14G2a, but mediates ADCC of GD2-positive melanoma cells in vitro about 100-fold more efficiently than 14G2a [202]. Early phase I clinical studies and retrospective analysis of single-agent ch14.18 treatment in patients with melanoma and neuroblastoma revealed that ch14.18 has considerable antitumor activity in neuroblastoma [203-205], but not in melanoma [206]. However, combination of ch14.18 with interleukin-2 [207] and GM-CSF plus IL-2 plus isotretinoin [208] results in enhancement of antitumor activity of ch14.18 in melanoma and neuroblastoma patients, respectively.

TRBs07 (Ektomun, Ektomab) is a bispecific, trifunctional antibody construct (Triomab) comparable to catumaxomab that originate from parental mouse anti-GD2 and anti-GD3 IgG2a mAb Me361 and rat anti-GD3 IgG2b mAb 26II6 [209]. This Triomab binds human CD3 as well as the gangliosides GD2 and GD3 with a preference for GD2, thereby redirecting and activating CD3-positive T-lymphocytes, which induce specific lysis of target cells expressing GD2, such as human melanoma cells and other neuroectodermal tumor cells [209]. Similar to catumaxomab, TRBs07 additionally binds via its Fc fragment to Fcγ-receptors on dendritic cells, macrophages and natural killer cells, and induces the secretion of cytokines such as IFN-γ, TNF-α, IL-2, IL-6 and IL-10 by peripheral blood mononuclear cells in vitro [209]. The Triomab Surek, which possesses the identical anti-GD2 binding arm as TRBs07, but binds to mouse CD3 instead of human CD3, has recently been shown to induce tumor eradication and protection against a second tumor challenge in a mouse melanoma model. Eradication of mouse melanoma was accompanied by the induction of tumor-specific T cells with defined melanoma-associated antigen specificity, induction of a humoral anti-tumor immune response, and generation of a long-term memory response against a second tumor challenge, indicating that Triomabs can generate potent tumor immunity against melanoma cells [137,138].

In view of the recent discovery that GD2 is expressed on human breast CSCs and promotes tumorigenesis in human breast cancer xenograft mice [193], mAbs and antibody constructs targeting GD2 may represent powerful therapeutic tools for the eradication of breast CSCs and the treatment of human breast cancer and other GD2-expressing tumors.
Anti-Lgr5

Lgr5 (leucine-rich-repeat containing G-protein-coupled receptor 5) is a seven-span transmembrane protein and the receptor and functional target for R-spondin proteins, which constitute secreted agonists of the canoical Wnt/β-catenin signaling pathway. Lgr5 therefore is a facultative Wnt receptor that mediates Wnt signal enhancement by soluble R-spondin proteins [210,211]. Lgr5 is expressed on Wnt/β-catenin-dependent adult stem cell populations of the intestine, colon and hair-follicle [212]. Expression of Lgr5 has been demonstrated on intestinal crypt stem cells, which are the cells-of-origin of intestinal cancer [213], indicating that Lgr5 is a functional marker of intestinal CSC involved in intestinal and colorectal carcinogenesis [214,215]. In patients with colorectal cancer, Lgr5 expression positively correlates with histological grade, invasion and metastasis, and inversely correlates with survival of patients, revealing an important role of Lgr5 in the progression and prognosis of colorectal cancer.

KM4056, a rat IgG2b mAb that specifically recognizes the N-terminal extracellular domain of human Lgr5, has been generated recently [217]. KM4056 binds with high affinity to human Lgr5 genetically expressed on the surface of Chinese hamster ovary (CHO) cells. In xenograft mice, KM4056 significantly inhibits tumor growth of human Lgr5-expressing CHO cells, demonstrating a strong anti-tumor activity of KM4056 in vivo [217].

Three rat IgG mAbs, 1D9, 4D11 and 9G5 that selectively bind endogenously expressed Lgr5 on colon CSCs isolated and enriched from human colorectal cancer samples have been developed and investigated very recently [210,218,219]. Using these mAbs, it was demonstrated that Lgr5 is a selective marker for human colon CSCs that is suitable for the identification, isolation, enrichment and functional characterization of human colon CSCs in vitro and in xenograft mice [218]. Although 1D9, 4D11 and 9G5 have been used hitherto for the identification and characterization of colon CSCs, it is conceivable that these or similar mAbs raised against Lgr5 will be exploited in the future as therapeutic tools to eradicate colon and intestinal CSCs [219].

Conclusions and Future Directions

The last years have highlighted the challenges and opportunities of selectively targeting CSCs, which are regarded as one of the main driving force in carcinogenesis and cancer. Although the rather novel CSC concept of carcinogenesis is mostly accepted to date, other relevant mechanisms and driving forces of carcinogenesis, including epigenetic modifications, genome instability, replicative immortality, immune evasion, reprogramming of energy metabolism, and most likely, a sophisticated conjunction of all of these mechanisms appears to be essential for the genesis of cancer [220-223].

Nevertheless, in line with the CSC concept of carcinogenesis [1-10], CSCs constitute adequately characterized cells and represent novel and translationally relevant targets for cancer therapy [5,15,49]. Unfortunately, CSCs exhibit a variety of intrinsic mechanisms of resistance to conventional chemotherapeutic drugs and radiation therapy, allowing them to survive standard cancer therapies and to initiate tumor recurrence and metastasis [5,15,16]. Fortunately, CSCs express virtually private cell surface proteins, including CD44, CD47, EpCAM, CD123, GD2, Lgr5, IGF-IR, DI4 and FZD receptors, which can be targeted specifically and readily with novel mAbs and antibody constructs, without inducing a considerable extent of collateral tissue damage and even an enrichment of CSCs observed with conventional cytostatic drugs and radiation therapy.

Significant advances have been made recently in the discovery, development and validation of novel mAbs and antibody constructs that selectively target CSCs, and the future clinical use of these novel immunotherapeutics may represent a powerful strategy for eradicating CSCs in cancer patients by exploiting the host’s immune system, thereby preventing tumor recurrence and metastasis, and, hopefully, contributing to the cure of cancer. There is recent evidence that the novel class of Triomab antibody constructs not only can effectively eradicate their target cells in a spatially- and temporally-fashion, but also are capable of inducing a long-lasting immunity against tumor and CSCs antigens, thereby fulfilling the criteria of a cancer vaccination effect. Other classes of antibodies targeting CSCs have recently been demonstrated to induce robust tumor regression in xenograft mice and in clinical studies, pointing out their potent activity against CSCs and cancer cells. Finally, the combination of mAbs and antibody constructs targeting CSCs with conventional cytostatic drugs, novel tumor-targeted drugs and radiation therapy as well as the establishment of appropriate biomarkers and the definition of novel clinical endpoints for monitoring the efficacy of combined and multimodal therapeutic strategies will be a challenge to improve future cancer treatment [224,225].

References
1. Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414: 105-111.
2. Pardal R, Clarke MF, Morrison SJ (2003) Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 3: 895-902.
3. Ward RJ, Dirks PB (2007) Cancer stem cells: at the headwaters of tumor development. Annu Rev Pathol 2: 175-189.
4. Dick JE (2008) Stem cell concepts renew cancer research. Blood 112: 4793-4807.
5. Frank NY, Schatton T, Frank MH (2010) The therapeutic promise of the cancer stem cell concept. J Clin Invest 120: 41-50.
6. Hermann PC, Bhaskar S, Cioffì M, Heeschen C (2010) Cancer stem cells in solid tumors. Semin Cancer Biol 20: 77-84.
7. Sell S (2010) On the stem cell origin of cancer. Am J Pathol 176: 2584-2594.
8. Clevers H (2011) The cancer stem cell: premises, promises and challenges. Nat Med 17: 313-319.
9. Magee JA, Piskounova E, Morrison SJ (2012) Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 21: 283-296.
10. Valant P, Bonnet D, De Maria R, Lapidot T, Copland M, et al. (2012) Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer 12: 767-775.
11. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, et al. (2006) Cancer stem cells–perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 6: 9339-9344.
12. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, et al. (2009) Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A 106: 13820-13825.
13. Tehranchi R, WoI JS, Anderson K, Buzza-Vidis N, Mizukami T, et al. (2010) Persistent malignant stem cells in del(5q) myelodysplasia in remission. N Engl J Med 363: 1025-1037.
14. Gerber JM, Smith BD, Ngwang B, Zhang H, Vala MS, et al. (2012) A clinically relevant population of leukemic CD34(+)/CD38(-) cells in acute myeloid leukemia. Blood 119: 3571-3577.
15. Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, et al. (2009) Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 8: 806-823.
16. Naujokat C, Steinhardt R (2012) Salinomycin as a drug for targeting human cancer stem cells. J Biomed Biotechnol 2012: 950658.
38. Yen WC, Fischer MM, Hynes M, Wu J, Kim E, et al. (2012) Anti-DLL4 has broad activity and safety of trastuzumab as a single agent in first-line treatment of HER2-positive metastatic breast cancer. Oncology 78: 141-149.

39. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, et al. (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6: 117-127.

40. Berms K, Horlings HM, Hennessy BT, Madriredo M, Hijmans EM, et al. (2007) A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12: 395-402.

41. Fabi A, Metro G, Di Benedetto A, Nistico C, Vici P, et al. (2010) Clinical significance of PTEN and p-Akt co-expression in HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies. Oncology 78: 1-149.

42. Kataoka Y, Mukohara T, Shinoda H, Saito N, Hiraiz M, et al. (2010) Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Ann Oncol 21: 255-262.

43. Hill R, Wu H (2009) PTEN, stem cells, and cancer stem cells. J Biol Chem 284: 11755-11759.

44. Dave B, Migliacce I, Gutierrez MC, Wu MF, Channess GC, et al. (2011) Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol 29: 166-173.

45. Wilhelm SM, Adnan L, Newell P, Villaneuva A, Lioet JM, et al. (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7: 3129-3140.

46. Carow CE, Levenstein M, Kaufmann SH, Chen J, Amin S, et al. (1996) Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flik2) in human leukemias. Blood 87: 1089-1096.

47. Morrison RS, Schleifer SM, Sun Y, Niermann KJ, Kim S, et al. (2011) Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis. J Natl Cancer Inst 103: 717-728.

48. Shackleton M, Quintana E, Fearon ER, Morrison SJ (2009) Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 138: 822-829.

49. McDermott SP, Wicha MS (2010) Targeting breast cancer stem cells. Mol Oncol 4: 404-419.

50. Naujokat C, Lauer S (2013) Targeting cancer stem cells with defined compounds and drugs. Anti-Cancer Agents Med Chem.

51. Naujokat C, Fuchs D, Opitz G (2010) Salinomycin in cancer: A new mission for an old agent. Mol Med Report 3: 559-569.

52. Li Y, Wicha MS, Schwartz SJ, Sun D (2011) Implications of cancer stem cell theory for cancer chemoprevention by natural dietary compounds. J Nutr Biochem 22: 799-806.

53. Deonarain MP, Kousparou CA, Epenetos AA (2009) Antibodies targeting cancer stem cells: a new paradigm in immunotherapy? MBs 1: 12-25.

54. Hoey T, Yen WC, Axelrod F, Basi J, Donigan L, et al. (2009) DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 5: 168-177.

55. Fischer M, Yen WC, Kapoun AM, Wang M, O'Young G, et al. (2011) Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations. Cancer Res 71: 1520-1525.

56. Yen WC, Fischer MM, Hynes M, Wu J, Kim E, et al. (2012) Anti-DLL4 has broad spectrum activity in pancreatic cancer dependent on targeting DLL4-Notch signaling in both tumor and vascular cells. Clin Cancer Res 18: 5374-5386.

57. Yen WC, Fischer M, Lewicki J, Gurney A, Hoey T (2010) Targeting cancer stem cells and vasculature by a novel anti-delta-like 4 ligand (DLL4) antibody inhibits
triple-negative breast cancer tumor growth and delays tumor recurrence. Cancer Res 70: Abstract nr 15.

61. Wen WC, Fischer M, Lewicki J, Gurney A, Hoey T (2011) Targeting cancer stem cells by a novel anti-frizzled antibody inhibits pancreatic tumor growth and induces differentiation. Cancer Res 71: Abstract nr 973.

62. Gurney A, Axelrod F, Bond CJ, Jain C, Charter C, et al. (2012) Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc Natl Acad Sci U S A 109: 11717-11722.

63. Lewicki J, Axelrod F, Beviglia L, Bond CJ Donigian L, et al. (2012) Development of a novel Wnt pathway antagonist antibody, OMP-18R5, that reduces tumor initiating cell frequency in breast cancer. Cancer Res 72: Abstract nr 3356.

64. Goodson S, Urquidi V, Tarin D (1999) CD44 cell adhesion molecules. Mol Pathol 52: 189-196.

65. Negi LM, Talegaonkar S, Jaggi M, Ahmad FJ, Iqbal Z, et al. (2012) Role of CD44 in tumour progression and strategies for targeting. J Drug Target 20: 561-573.

66. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100: 3983-3988.

67. Vira D, Basak SK, Veena MS, Wang MB, Batra RK, et al. (2012) Cancer stem cells, microRNAs, and therapeutic strategies including natural products. Cancer Metastasis Rev 31: 733-751.

68. Gaffari S, Dougherty GJ, Lansdorp PM, Eaves AC, Eaves CJ (1995) Differentiation-associated changes in CD44 isoform expressing during normal hematopoiesis and their alteration in chronic myeloid leukemia. Blood 86: 2979-2985.

69. Gaffari S, Dougherty GJ, Eaves AC, Eaves CJ (1996) Altered patterns of CD44 epitope expression in human chronic and acute myeloid leukemia. Leukemia 10: 1773-1781.

70. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE (2006) Targeting of CD44 eradicates human acute myeloid leukemia stem cells. Nat Med 12: 1167-1174.

71. Zöller M (2011) CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer 11: 254-267.

72. Ghosh SC, Nesiltan Alpay S, Klostergaard J (2012) CD44: a validated target for improved delivery of cancer therapeutics. Expert Opin Ther Targets 16: 635-650.

73. Huet S, Groux H, Caillou B, Valentin H, Prieur AM, et al. (1989) CD44 contributes to T cell activation. J Immunol 143: 798-801.

74. Charrad RS, Li Y, Delpech B, Ballardin N, clay D, et al. (1999) Ligation of the CD44 adhesion molecule reverses blockage of differentiation in human acute myeloid leukemia. Nat Med 5: 669-676.

75. Charrad RS, Li Y, Delpech B, Ballardin N, clay D, et al. (1999) Ligation of the CD44 adhesion molecule reverses blockage of differentiation in human acute myeloid leukemia. Nat Med 5: 669-676.

76. Charrad RS, Gadhoum Z, Qi J, Glachant A, Allouche M, et al. (2002) Effects of anti-CD44 monoclonal antibodies on differentiation and apoptosis of human myeloid leukemia cell lines. Blood 99: 290-299.

77. Gadhoum Z, Delaunay J, Maquarre E, Durand L, Lancereaux V, et al. (2004) The CD44 isoforms are heterogenously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers. BMC Cancer 11: 418.

78. Perez A, Neskey DM, Wen J, Goodwin JW, slingerland J, et al. (2012) Targeting CD44 in head and neck squamous cell carcinoma (HNSCC) will a new humanized antibody RO5429083. Cancer Res 72: Abstract nr 2521.

79. Hama T, Yuzu M, Saito Y, Ouchi J, Kondo S, et al. (2009) Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma. Oncologist 14: 900-908.

80. Open-label multicenter 2-arm phase I study of RO5429083 with dose escalation and extension cohorts, and imaging cohorts with RO5429083 and 89Zr-labeled RO5429083, in patients with metastatic and/or locally advanced, CD44-expressing, malignant solid tumors. NCT01358903, ClinicalTrials.gov.

81. Open-label, multicenter, dose escalation phase 1a study of RO5429083, administered as intravenous infusion alone or in combination with cytoreductive agents in patients with acute myelogenous leukemia (AML). NCT01641250, ClinicalTrials.gov.

82. Bellotos PC, Gillath JF, August JT (1990) Homotypic cell aggregation induced by anti-CD44(Pgp-1) monoclonal antibodies and related to CD44(Pgp-1) expression. J Immunol 144: 1661-1670.

83. Tang W, Hao X, He F, Li L, Xu L (2011) Anti-CD44 antibody treatment inhibits pancreatic cancer metastasis and post-radiotherapy recurrence. Cancer Res 71: Abstract nr 565.

84. Masuko K, Okazaki S, Satoh M, Tanaka G, Ikeda T, et al. (2012) Anti-tumor effect against human cancer xenografts by a fully human monoclonal antibody to a variant 8-epitope of CD44R1 expressed on cancer stem cells. PLoS One 7: e29729.

85. Olsson E, Honeth G, Bendahl PO, saal LH, Gruvberger-Saal S, et al. (2011) CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers. BMC Cancer 11: 418.

86. Brown EJ, Frazier WA (2001) Integrin-associated protein (CD47) and its ligands. Trends Cell Biol 11: 130-136.

87. Barclay AN, Brown MH (2006) The SIRP family of receptors and immune regulation. Nat Rev Immunol 6: 457-464.

88. Subramanian S, Parthasarathy R, Sen S, Boder ET, discher DE (2006) Species- and cell-type-specific interactions between CD47 and human SIRPalpha. Blood 107: 2549-2556.

89. Barclay AN (2009) Signal regulatory protein alpha (SIRPα)/CD47 interaction and function. Curr Opin Immunol 21: 47-52.

90. Oldenborg PA, Gresham HD, Lindberg FP (2001) CD47-signal regulatory protein alpha (SIRPa) regulates Fc7 and complement receptor-mediated phagocytosis. J Exp Med 193: 855-862.

91. Kinchen JM, Ravichandran KS (2009) Phagocytic signaling: you can touch, but you can’t eat. Curr Biol 18: R521-R524.

92. Subramanian S, Parthasarathy R, Sen S, Boder ET, discher DE (2006) Species- and cell-type-specific interactions between CD47 and human SIRPalpha. Blood 107: 2549-2556.

93. Oldenborg PA, Gresham HD, Lindberg FP (2001) CD47-signal regulatory protein alpha (SIRPa) regulates Fc7 and complement receptor-mediated phagocytosis. J Exp Med 193: 855-862.

94. Kinchen JM, Ravichandran KS (2009) Phagocytic signaling: you can touch, but you can’t eat. Curr Biol 18: R521-R524.

95. Jaiswal S, Chao MP, Majeti R, Weissman IL (2010) Macrophages as mediators of tumor immunosurveillance. Trends Immunol 31: 212-219.

96. Jaiswal S, Chao MP, Majeti R, Weissman IL (2010) Macrophages as mediators of tumor immunosurveillance. Trends Immunol 31: 212-219.

97. Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, et al. (2010) Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142: 699-713.

98. Jaiswal S, Chao MP, Majeti R, Weissman IL (2010) Macrophages as mediators of tumor immunosurveillance. Trends Immunol 31: 212-219.

99. Chao MP, Weissman IL, Majeti R (2010) Macrophages as mediators of tumor immunosurveillance. Trends Immunol 31: 212-219.

100. Willingham SB, Volker MP, Gentles AJ, Sahoo D, Dalebra P, et al. (2012) The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A 109: 6662-6667.

101. Majeti R, Chao MP, Alizadeh AA, Fang WW, Jaiswal S, et al. (2009) CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138: 286-299.

102. Chan KS, Espinosa I, Chao M, Wong D, Ailles L, et al. (2009) Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci U S A 106: 14016-14021.

103. Chao MP, Tang C, Pachynski RK, Chin R, Majeti R, et al. (2011) Extranalod...
dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. Blood 118: 4989-4991.

104. Chao MP, Alizadeh AA, Tang C, Jan M, Weissman-Tsukamoto R, et al. (2011) Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res 71: 1374-1384.

105. Kim D, Wang J, Willingham SB, Martin R, Wernig G, et al. (2012) Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells. Leukemia 26: 2538-2545.

106. Liu J, Weissman IL, Majeti R (2011) Humanized and chimeric monoclonal antibodies to CD47. International Patent, WO 2011/143624, PCT/US2011/036535.

107. Edris B, Weiskopf K, Volkmer AK, Volkmer JP, Willingham SB, et al. (2012) Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proc Natl Acad Sci U S A 109: 6656-6661.

108. Sun Q, Woodcock JM, Rapoport A, Stoms FC, Korpelainen EJ, et al. (1996) Monoclonal antibody 7G3 recognizes the N-terminal domain of the human interleukin-3 (IL-3) receptor alpha-chain and functions as a specific IL-3 receptor antagonist. Blood 87: 83-92.

109. Jordan CT, Upchurch D, Szilvassy SJ, Guzman ML, Howard DS, et al. (2000) The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 14: 1777-1784.

110. Testa U, Riccioni R, Matti S, Coccia E, Stellacci E, et al. (2002) Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood 100: 2980-2988.

111. Jin L, Lee EM, Ramshaw HS, Busfeld SJ, Peoppl AG, et al. (2009) Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha, eliminates human acute myeloid leukemic stem cells. Cell Stem Cells 5: 31-42.

112. Vergez F, Green AS, Tamburini J, Sarry JE, Gaillard B, et al. (2011) High levels of CD34+CD33low/CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemias: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study. Haematologica 96: 1792-1798.

113. Roberts AW, He S, Ritchie D, Hertzberg MS, Kerridge I, et al. (2010) A phase I study of anti-CD123 monoclonal antibody (mAb) CSL360 targeting leukaemia stem cells (LSC). In J Clin Oncol 28: Abstract nr e13012.

114. A phase 1 study of CSL362 (Anti-IL3Ra/Anti-CD123 monoclonal antibody) in patients with CD123+ acute myeloid leukemia in complete remission or complete remission with incomplete platelet recovery at high risk for early relapse. NCT01632852, ClinicalTrials.gov.

115. Kuo SR, Wong L, Liu JS (2012) Engineering a CD123xCD3 bispecific scFv antibody for the treatment of leukemia and elimination of leukemia stem cells. Protein Eng Des Sel 25: 561-569.

116. Sebastian M, Kuenmmel A, Schmidt M, Schmittl A (2009) Catumaxomab: a bispecific trivalent antibody. Drugs Today 45: 589-597.

117. Seimetz D, Lindhofer H, Bokemeyer C (2010) Development and approval of the trifunctional antibody catumaxomab (anti-EP CAM x anti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev 36: 458-467.

118. Ruf P, Lindhofer H (2001) Induction of a long-lasting antitumor immunity by a trifunctional antibody. Blood 98: 2526-2534.

119. Essner N, Ruf P, Mysliwietz J, Lindhofer H, Mockat R (2012) Trifunctional bispecific antibodies induce tumor-specific T cells and elicit a vaccination effect. Cancer Res 72: 3958-3966.

120. Ruf P, Schäffer B, Essner N, Mockat R, Hess J, et al. (2012) Ganglioside GD2-specific trifunctional surrogate antibody Serek demonstrates therapeutic activity in a mouse melanoma model. J Transl Med 10: 219.

121. Sebastian M, Kiewe P, Schmittl M, Schmittl A (2009) Catumaxomab: a bispecific trivalent antibody. Drugs Today 45: 589-597.

122. Ströhlke MA, Lordick F, Rüttiger D, Grützner KU, Schlemm M, et al. (2011) Immunotherapeutic of periitonial carcinomatosis with the antibody catumaxomab in colon, gastric or pancreatic cancer: an open-label, multicenter, phase Ib study. Onkolologie 34: 101-108.

123. Jäger M, Scherber A, Ruf P, Hess J, Hennig M, et al. (2012) Immunomonitoring of the antibody Catumaxomab (anti-EP CAM x anti-CD3) as follows a phase 1/2 study I. J Cancer Immunol 32: 195-202.

124. Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, et al. (2010) The functional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase III trial. Int J Cancer 127: 2209-2221.

125. Ströhlein MA, Lordick F, Rüttiger D, Dürrenberger K, Schlemm M, et al. (2011) Immunotherapeutical of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase II trial. Onkologie 34: 101-108.
144. Sebastian M, Passlick B, Friccius-Quecke H, Jäger M, Lindhofer H, et al. (2007) Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study. Cancer Immunol Immunother 56: 1637-1644.

145. A phase I, open label, dose escalating study to evaluate the safety and tolerability of ascending intravenous (i.v.) doses of catumaxomab in epithelial cancer patients. NCT01320020, ClinicalTrials.gov.

146. Kurtz JE, Dufour P (2010) Adegatubumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside. Expert Opin Biol Ther 10: 951-958.

147. Munz M, Murr A, Kvesic M, Rau D, Mangold S, et al. (2010) Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies. Cancer Cell Int 10: 44.

148. Reichert JM (2012) Marketed therapeutic antibodies compendium. MAbs 4: 413-415.

149. Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8: 915-928.

150. Gao J, Chang YS, Jallal B, Viner J (2012) Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology. Cancer Res 72: 3-12.

151. Frasca F, Pandini G, Sciacca L, Pezzino V, Squitrito S, et al. (2008) The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem 114: 23-37.

152. Badzio A, Wynes MW, Dzialdowski R, Merrick DT, Pardo M, et al. (2010) Increased insulin-like growth factor 1 receptor protein expression and gene copy number in small cell lung cancer. J Thorac Oncol 5: 1905-1911.

153. Moreau P, Cavalli F, Lesiu X, Hulin C, Amiot M, et al. (2011) Phase I study of the anti-insulin-like growth factor 1 receptor (IGF-1R)-monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma. Leukemia 25: 872-874.

154. Macaulay VM, Middleton MR, Protheroe AS, Tolcher A, Dieras V, et al. (2012) Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors. Ann Oncol 23: 150-158.

155. Pollak M (2012) The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 12: 159-169.

156. Baserga R (2012) The decline and fall of the IGF-I receptor. J Cell Physiol .

157. Dallas NA, Xia L, Fan F, Gray MJ, Gaur P, et al. (2009) Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-factor-1 receptor inhibition. Cancer Res 69: 1951-1957.

158. Hart LS, Dolloff NG, Dicker DT, Koumenis C, Christensen JG, et al. (2011) Increased insulin-like growth factor 1 receptor protein expression and gene copy number in small cell lung cancer. J Thorac Oncol 5: 1905-1911.

159. Descamps G, Gomez-Bougie P, Venot C, Moreau P, Bataille R, et al. (2009) A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45. Br J Cancer 100: 366-369.

160. Gualberto A, Karp DD (2009) Development of the monoclonal antibody figitumumab, targeting the insulin-like growth factor-1 receptor, for the treatment of patients with non-small-cell lung cancer. Clin Lung Cancer 10: 273-280.

161. Gualberto A (2010) Figitumumab (CP-751,871) for cancer therapy. Expert Opin Biol Ther 10: 575-585.

162. Scaglotti GV, Novello S (2012) The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors. Cancer Treat Rev 38: 292-302.

163. Bridges E, Oon CE, Harris A (2011) Notch regulation of tumor angiogenesis. Future Oncol 7: 569-588.

164. Takebe N, Harris PJ, Warren RQ, Ivy SP (2011) Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 8: 97-106.

165. Wang J, Sullenger BA, Rich JN (2012) Notch signaling in cancer stem cells. Adv Exp Med Biol 727: 174-185.

166. Patel NS, Li JL, Generali D, Poulos R, Cranston DW, et al. (2005) Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res 65: 8960-8967.

167. Nogueira-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, et al. (2006) Blockade ofDll4 inhibits tumor growth by promoting non-productive angiogenesis. Nature 444: 1032-1037.

168. Kuhnsert F, Krinesher JR, Thurstong G (2011) Dll4-Notch signaling as a therapeutic target in tumor angiogenesis. Vasc Cell 3: 20.

169. Beviglia L, Yeung P, Fischer M, Yen WC, Lewicki J, et al. (2011) Anti-DLL4 treatment inhibits melanoma tumor growth, recurrence, metastases, and reduces frequency of cancer stem cells in a clinically relevant tumor model in NOD/SCID mice. Cancer Res 71: Abstract nr 2834.

170. Beviglia L, Yeung P, Fischer M, Yen WC, Gurney A, et al. (2012) Anti-DLL4 reduces tumor growth and tumor-origin in B-RAF V600E melanomas including those with acquired resistance to B-RAF inhibitors, Cancer Res 72: Abstract nr LB-196.

171. Yen WC, Fischer M, Lewicki J, Gurney A, Hoey T (2012) Targeting cancer stem cells by an anti-DLL4 antibody inhibits epithelial-to-mesenchymal transition, delays tumor recurrence and overcomes drug resistance in breast and pancreatic cancer. Cancer Res 72: Abstract nr 3357.

172. A phase 1 dose escalation study of OMP-21M18 in subjects with solid tumors. NCT00744562, ClinicalTrials.gov.

173. A phase 1b study of FOLFiRIR plus OMP-12M18 as 1st or 2nd-line treatment in subjects with metastatic colorectal cancer. NCT01199942, ClinicalTrials.gov.

174. A phase 1b study of gencatimib plus OMP-21M18 as 1st-line treatment in subjects with locally advanced or metastatic pancreatic cancer. NCT01199925, ClinicalTrials.gov.

175. A phase 1b study of carboplatin and pemetrexed plus OMP-21M18 as 1st-line treatment in subjects with non-squamous non-small cell lung cancer. NCT01189968, ClinicalTrials.gov.

176. A phase 1, multiple-dose study of the safety and tolerability of single agent REGN4241 administered every 2 or 3 weeks in patients with advanced solid malignancies. NCT00871559, ClinicalTrial.gov.

177. Schulte G (2010) International Union of Basic and Clinical Pharmacology. LXXX. The class Frizzled receptors. Pharmacol Rev 62: 632-667.

178. Koval A, Purvarov V, Egger-Adam D, Katanavae VL (2011) Yellow submarine of the Wnt/Frizzled signaling: submerging from the G protein harbor to the targets. Biochem Pharmacol 82: 1311-1319.

179. King TD, Zhang W, Suto MJ, Li Y (2012) Flazzed7 as an emerging target for cancer therapy. Cell Signal 24: 846-851.

180. King TD, Suto MJ, Li Y (2012) The Wnt/β-catenin signaling pathway: a potential therapeutic target in the treatment of triple negative breast cancer. J Cell Biochem 113: 13-18.

181. Ueno K, Hirata H, Hinoda Y, Daihri R (2012) Fizzled homolog proteins, microRNAs and Wnt signaling in cancer. Int J Cancer.

182. A phase 1 dose escalation study of OMP-18RS in subjects with solid tumors. NCT01345201, ClinicalTrials.gov.

183. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, et al. (1997) CD133-2, a novel isoform of human insulin receptors and IGF-I receptors in cancer and other diseases. Arch Pathol. 1025-1032.

184. Yu Y, Flint A, Dvorin EL, Bischoff J (2002) AC133-2, a novel isoform of human insulin receptors and IGF-I receptors in cancer and other diseases. Arch Pathol. 1025-1032.

185. King TD, Zhang W, Suto MJ, Li Y (2012) Flazzed7 as an emerging target for cancer therapy. Cell Signal 24: 846-851.

186. Patel NS, Li JL, Generali D, Poulos R, Cranston DW, et al. (2005) Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res 65: 8960-8967.
